Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Equity Average (2016 - 2025)

Editas Medicine (EDIT) has disclosed Equity Average for 10 consecutive years, with $16.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 91.99% to $16.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.3 million, a 91.99% decrease, with the full-year FY2024 number at $241.7 million, down 31.9% from a year prior.
  • Equity Average was $16.3 million for Q3 2025 at Editas Medicine, down from $40.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $625.7 million in Q2 2021 to a low of $16.3 million in Q3 2025.
  • A 5-year average of $352.3 million and a median of $358.7 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 107.56% in 2021, then plummeted 91.99% in 2025.
  • Editas Medicine's Equity Average stood at $570.2 million in 2021, then crashed by 32.01% to $387.7 million in 2022, then decreased by 8.49% to $354.8 million in 2023, then plummeted by 56.32% to $155.0 million in 2024, then plummeted by 89.47% to $16.3 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Equity Average are $16.3 million (Q3 2025), $40.8 million (Q2 2025), and $98.3 million (Q1 2025).